Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Affymetrix Charts. Click Here for more Affymetrix Charts.](/p.php?pid=staticchart&s=N%5EAFFX&p=8&t=15)
Affymetrix and QIAGEN to Collaborate on siRNA Research Using GeneChip(R)
Technology
VENLO, The Netherlands, and SANTA CLARA, Calif., Oct. 31
/PRNewswire-FirstCall/ -- QIAGEN N.V. and Affymetrix, Inc., today announced
that they have entered into a collaboration to optimise QIAGEN siRNA-mediated
gene silencing using Affymetrix GeneChip(R) microarray technology. The
collaboration is intended to develop optimised procedures that can be
standardized to analyse gene silencing effects on a genome-wide basis.
QIAGEN has a leading position in gene silencing by siRNA using synthesis
technology based on a proprietary chemistry (TOM amidites), and on transfection
methods and kits for introduction of siRNA into target cells. The ability of
market leading Affymetrix GeneChip expression arrays to provide a comprehensive
picture of all the protein-coding content in the human genome enables
researchers to determine on a whole genome scale, on- and off-target effects of
siRNA-mediated gene silencing.
Optimised protocols and data resulting from the collaboration describing the
benefits of using the two technologies together will be provided to researchers
in technical notes.
"Use of siRNA as a tool to impact important biological pathways is a rapidly
growing area of research in basic biology and therapeutic development," said
Trevor J. Nicholls, Ph.D., Affymetrix's Chief Commercial Officer. "The
whole-genome view that Affymetrix arrays offer will give researchers a more
complete understanding of the downstream effects of siRNAs in their experiments
and clinical research. We are pleased to be working with QIAGEN in this
exciting area. This relationship complements our recently announced
collaboration with PreAnalytiX GmbH to develop sampling protocols in clinical
research."
"This collaboration adds another cornerstone to the already existing
partnerships with Affymetrix," said Dr. Ulrich Schriek, Vice President Corporate
Business Development of QIAGEN. "It will strengthen QIAGEN's presence in what
has evolved to one of the most dynamic areas of today's functional genomics
market. The combination of our synthetic siRNA and transfection products with
the market's leading array technology will set new standards and is ideally
suited to provide an optimal tool set to researchers studying complex genetic
pathways and networks."
About QIAGEN
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the
United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia,
Norway, Austria and Canada, believes it is the world's leading provider of
innovative enabling technologies and products for the separation, purification
and handling of nucleic acids. The Company has developed a comprehensive
portfolio of more than 320 proprietary, consumable products for nucleic acid
separation, purification and handling, nucleic acid amplification, as well as
automated instrumentation, synthetic nucleic acid products and related services.
QIAGEN's products are sold in more than 42 countries throughout the world to
academic research markets and to leading pharmaceutical and biotechnology
companies. In addition, the Company is positioning its products for sale into
developing commercial markets, including DNA sequencing and genomics, nucleic
acid-based molecular diagnostics, and genetic vaccination and gene therapy.
QIAGEN employs approximately 1,600 people worldwide. Further information on
QIAGEN can be found at http://www.qiagen.com/.
About Affymetrix:
Affymetrix is a pioneer in creating breakthrough tools that are driving the
genomic revolution. By applying the principles of semiconductor technology to
the life sciences, Affymetrix develops and commercializes systems that enable
scientists to improve the quality of life. The Company's customers include
pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non-profit research
institutes. Affymetrix offers an expanding portfolio of integrated products and
services, including its integrated GeneChip platform, to address growing markets
focused on understanding the relationship between genes and human health.
Additional information on Affymetrix can be found at
http://www.affymetrix.com/.
Certain of the statements contained in this news release may be considered
forward-looking statements within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products and markets and operating results
are forward-looking, such statements are based on current expectations that
involve a number of uncertainties and risks. Such uncertainties and risks
include, but are not limited to, risks associated with management of growth and
international operations (including the effects of currency fluctuations and
risks of dependency on logistics), variability of operating results, the
commercial development of the DNA sequencing, genomics and synthetic nucleic
acid-related markets, nucleic acid-based molecular diagnostics market, and
genetic vaccination and gene therapy markets, competition, rapid or unexpected
changes in technologies, fluctuations in demand for QIAGEN's, products
(including seasonal fluctuations), difficulties in successfully adapting
QIAGEN's products to integrated solutions and producing such products, the
ability of QIAGEN to identify and develop new products and to differentiate its
products from competitors, and the integration of acquisitions of technologies
and businesses. For further information, refer to the discussion in reports
that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).
DATASOURCE: QIAGEN N.V.
CONTACT: Peer M. Schatz, Chief Financial Officer of QIAGEN N.V.,
+49-2103-29-11702, or , or Dr. Solveigh Maehler, Manager
Investor Relations of QIAGEN N.V., +49-2103-29-11710, or
; or Wes Conard, Senior Manager, Public Relations
of Affymetrix, Inc., +1-408-731-5791, or , or Doug
Farrell, Vice President for Investor Relations of Affymetrix, Inc.,
+1-408-731-5285, or
Web site: http://www.qiagen.com/
http://www.affymetrix.com/